Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 195 | 2025 | 21188 | 11.980 |
Why?
|
Receptor, erbB-2 | 107 | 2025 | 2606 | 11.230 |
Why?
|
Immunoconjugates | 37 | 2025 | 976 | 7.650 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 108 | 2025 | 11886 | 5.910 |
Why?
|
Paclitaxel | 28 | 2024 | 1735 | 3.730 |
Why?
|
Camptothecin | 28 | 2025 | 600 | 3.660 |
Why?
|
Receptors, Estrogen | 35 | 2025 | 2252 | 3.170 |
Why?
|
Aminopyridines | 21 | 2024 | 580 | 3.030 |
Why?
|
Receptors, Progesterone | 22 | 2024 | 1159 | 3.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 15 | 2024 | 566 | 2.980 |
Why?
|
Neoadjuvant Therapy | 35 | 2024 | 2909 | 2.880 |
Why?
|
Benzimidazoles | 17 | 2024 | 864 | 2.860 |
Why?
|
Ketones | 5 | 2024 | 183 | 2.430 |
Why?
|
Furans | 5 | 2024 | 202 | 2.400 |
Why?
|
Cyclin-Dependent Kinase 6 | 8 | 2024 | 354 | 2.260 |
Why?
|
Antineoplastic Agents | 31 | 2024 | 13698 | 1.970 |
Why?
|
Maytansine | 4 | 2022 | 88 | 1.800 |
Why?
|
Chemotherapy, Adjuvant | 27 | 2024 | 3554 | 1.710 |
Why?
|
Protein Kinase Inhibitors | 23 | 2024 | 5707 | 1.690 |
Why?
|
Pyridines | 14 | 2024 | 2895 | 1.660 |
Why?
|
Anilides | 6 | 2020 | 414 | 1.640 |
Why?
|
Molecular Targeted Therapy | 11 | 2024 | 2830 | 1.590 |
Why?
|
Female | 236 | 2025 | 397515 | 1.550 |
Why?
|
Immunotherapy | 19 | 2024 | 4756 | 1.480 |
Why?
|
Neoplasm Metastasis | 30 | 2024 | 4926 | 1.260 |
Why?
|
Neoplasm Staging | 33 | 2024 | 11262 | 1.250 |
Why?
|
Humans | 279 | 2025 | 768970 | 1.230 |
Why?
|
Lung Diseases, Interstitial | 4 | 2024 | 940 | 1.160 |
Why?
|
Inflammatory Breast Neoplasms | 6 | 2024 | 154 | 1.150 |
Why?
|
Endocrine System Diseases | 3 | 2018 | 250 | 1.150 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2024 | 9442 | 1.050 |
Why?
|
Breast Neoplasms, Male | 7 | 2024 | 212 | 1.030 |
Why?
|
Brain Neoplasms | 13 | 2025 | 9213 | 1.020 |
Why?
|
Disease-Free Survival | 20 | 2024 | 6856 | 0.960 |
Why?
|
Aromatase Inhibitors | 3 | 2024 | 519 | 0.950 |
Why?
|
Cisplatin | 2 | 2021 | 1661 | 0.940 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2024 | 1105 | 0.890 |
Why?
|
Tumor Microenvironment | 11 | 2024 | 3952 | 0.880 |
Why?
|
Middle Aged | 112 | 2025 | 223737 | 0.850 |
Why?
|
Tetrahydronaphthalenes | 1 | 2023 | 85 | 0.830 |
Why?
|
Clinical Trials as Topic | 9 | 2024 | 8055 | 0.770 |
Why?
|
Neoplasms | 23 | 2024 | 22389 | 0.750 |
Why?
|
Piperazines | 7 | 2024 | 2553 | 0.730 |
Why?
|
Aged | 86 | 2025 | 171786 | 0.730 |
Why?
|
Neutropenia | 5 | 2023 | 893 | 0.720 |
Why?
|
Prognosis | 32 | 2025 | 30046 | 0.680 |
Why?
|
Research Subjects | 1 | 2021 | 249 | 0.660 |
Why?
|
Adult | 89 | 2025 | 223851 | 0.660 |
Why?
|
Quinoxalines | 3 | 2016 | 297 | 0.640 |
Why?
|
Estrogen Receptor alpha | 2 | 2023 | 581 | 0.640 |
Why?
|
Drug Resistance, Neoplasm | 13 | 2025 | 5342 | 0.640 |
Why?
|
Maximum Tolerated Dose | 7 | 2024 | 899 | 0.630 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1060 | 0.630 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 162 | 0.620 |
Why?
|
Endpoint Determination | 1 | 2021 | 594 | 0.610 |
Why?
|
Pyrimidinones | 1 | 2020 | 386 | 0.600 |
Why?
|
Taxoids | 4 | 2023 | 668 | 0.600 |
Why?
|
Treatment Outcome | 45 | 2024 | 65480 | 0.580 |
Why?
|
Quinolines | 4 | 2019 | 772 | 0.570 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2020 | 1093 | 0.560 |
Why?
|
Antigens, Neoplasm | 10 | 2024 | 2001 | 0.560 |
Why?
|
Quality of Life | 15 | 2024 | 13510 | 0.560 |
Why?
|
Pyrazoles | 3 | 2024 | 2029 | 0.540 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2024 | 1535 | 0.540 |
Why?
|
Amenorrhea | 2 | 2021 | 484 | 0.520 |
Why?
|
Antigens, Surface | 1 | 2020 | 1616 | 0.510 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2016 | 567 | 0.500 |
Why?
|
Pyrrolidinones | 1 | 2015 | 116 | 0.480 |
Why?
|
Fluorouracil | 2 | 2022 | 1655 | 0.450 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1120 | 0.450 |
Why?
|
Genomics | 9 | 2024 | 5928 | 0.450 |
Why?
|
Nitriles | 5 | 2024 | 990 | 0.450 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2020 | 2884 | 0.440 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 550 | 0.440 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 10400 | 0.440 |
Why?
|
Deoxycytidine | 2 | 2018 | 888 | 0.430 |
Why?
|
Antibodies, Monoclonal | 6 | 2021 | 9264 | 0.430 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 906 | 0.420 |
Why?
|
Biological Products | 1 | 2022 | 947 | 0.420 |
Why?
|
Thyroid Diseases | 4 | 2024 | 385 | 0.410 |
Why?
|
Mastectomy | 5 | 2022 | 1850 | 0.400 |
Why?
|
Diarrhea | 7 | 2024 | 1320 | 0.400 |
Why?
|
Neoplasm, Residual | 4 | 2024 | 1019 | 0.390 |
Why?
|
Mutation | 19 | 2024 | 30266 | 0.380 |
Why?
|
Cell Adhesion Molecules | 6 | 2024 | 1614 | 0.380 |
Why?
|
Cyclophosphamide | 6 | 2022 | 2227 | 0.380 |
Why?
|
Sulfonamides | 3 | 2016 | 1981 | 0.370 |
Why?
|
Breast | 6 | 2023 | 1976 | 0.370 |
Why?
|
Infusions, Intravenous | 4 | 2021 | 2231 | 0.360 |
Why?
|
Aged, 80 and over | 25 | 2024 | 59739 | 0.360 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2015 | 242 | 0.360 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 647 | 0.340 |
Why?
|
Mastectomy, Segmental | 4 | 2021 | 960 | 0.340 |
Why?
|
Quinazolines | 6 | 2024 | 1373 | 0.340 |
Why?
|
Purines | 4 | 2023 | 615 | 0.340 |
Why?
|
Polyethylene Glycols | 5 | 2022 | 1197 | 0.340 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4056 | 0.330 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2021 | 640 | 0.320 |
Why?
|
Survival Rate | 9 | 2025 | 12873 | 0.320 |
Why?
|
Follow-Up Studies | 14 | 2025 | 39394 | 0.310 |
Why?
|
Tumor Burden | 5 | 2021 | 1913 | 0.310 |
Why?
|
Hormones | 6 | 2023 | 870 | 0.300 |
Why?
|
Drug Administration Schedule | 5 | 2020 | 4862 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 7 | 2024 | 6547 | 0.290 |
Why?
|
Carcinoma | 1 | 2019 | 2340 | 0.290 |
Why?
|
Disease Management | 4 | 2020 | 2537 | 0.280 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2024 | 2460 | 0.280 |
Why?
|
Referral and Consultation | 1 | 2020 | 3628 | 0.280 |
Why?
|
Albumins | 2 | 2020 | 577 | 0.280 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2634 | 0.270 |
Why?
|
Retinoblastoma Binding Proteins | 2 | 2024 | 101 | 0.270 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2024 | 70 | 0.260 |
Why?
|
Estrogens | 2 | 2024 | 1536 | 0.260 |
Why?
|
Immunologic Factors | 4 | 2023 | 1597 | 0.260 |
Why?
|
Research Design | 2 | 2023 | 6214 | 0.260 |
Why?
|
Attitude of Health Personnel | 1 | 2020 | 3928 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8664 | 0.260 |
Why?
|
Triazoles | 3 | 2017 | 904 | 0.260 |
Why?
|
Survival Analysis | 7 | 2021 | 10115 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 5434 | 0.260 |
Why?
|
Filgrastim | 3 | 2020 | 131 | 0.260 |
Why?
|
Medical Oncology | 6 | 2024 | 2350 | 0.260 |
Why?
|
Combined Modality Therapy | 5 | 2021 | 8559 | 0.260 |
Why?
|
Lymphopenia | 1 | 2008 | 300 | 0.260 |
Why?
|
Oxazoles | 3 | 2024 | 199 | 0.260 |
Why?
|
Receptor, erbB-3 | 2 | 2016 | 143 | 0.250 |
Why?
|
Ki-67 Antigen | 3 | 2023 | 628 | 0.250 |
Why?
|
DNA Copy Number Variations | 4 | 2024 | 2055 | 0.250 |
Why?
|
Young Adult | 15 | 2024 | 60131 | 0.240 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2145 | 0.240 |
Why?
|
Palliative Care | 1 | 2020 | 3644 | 0.230 |
Why?
|
Breast Diseases | 1 | 2007 | 442 | 0.230 |
Why?
|
BRCA2 Protein | 3 | 2023 | 803 | 0.220 |
Why?
|
Physical Fitness | 3 | 2017 | 744 | 0.220 |
Why?
|
Receptors, Androgen | 2 | 2024 | 1091 | 0.220 |
Why?
|
Doxorubicin | 4 | 2020 | 2234 | 0.210 |
Why?
|
Anthracyclines | 3 | 2021 | 286 | 0.210 |
Why?
|
Exercise Therapy | 3 | 2020 | 939 | 0.210 |
Why?
|
Epirubicin | 1 | 2022 | 81 | 0.210 |
Why?
|
Axilla | 2 | 2023 | 625 | 0.210 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 3941 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10765 | 0.210 |
Why?
|
Biopsy | 4 | 2024 | 6805 | 0.200 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.200 |
Why?
|
Androstadienes | 1 | 2024 | 348 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2021 | 878 | 0.200 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2024 | 3671 | 0.200 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1156 | 0.200 |
Why?
|
Sarcoidosis | 1 | 2007 | 535 | 0.190 |
Why?
|
Sulfides | 1 | 2022 | 171 | 0.190 |
Why?
|
Stroke Volume | 1 | 2016 | 5622 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2021 | 53 | 0.190 |
Why?
|
Thyrotoxicosis | 2 | 2019 | 85 | 0.190 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2021 | 45 | 0.190 |
Why?
|
Drug Interactions | 2 | 2023 | 1418 | 0.190 |
Why?
|
Cohort Studies | 8 | 2024 | 41808 | 0.190 |
Why?
|
Lymph Nodes | 3 | 2023 | 3473 | 0.180 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2023 | 737 | 0.180 |
Why?
|
Endocrine Glands | 2 | 2018 | 101 | 0.180 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2021 | 43 | 0.180 |
Why?
|
Sweden | 1 | 2024 | 1382 | 0.180 |
Why?
|
SEER Program | 5 | 2024 | 1473 | 0.170 |
Why?
|
Cell Cycle Proteins | 3 | 2020 | 3450 | 0.170 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 933 | 0.170 |
Why?
|
Gene Expression Profiling | 4 | 2024 | 9549 | 0.170 |
Why?
|
Fatigue | 5 | 2022 | 1557 | 0.170 |
Why?
|
Meningeal Carcinomatosis | 1 | 2020 | 66 | 0.170 |
Why?
|
Antigen Presentation | 2 | 2023 | 1252 | 0.170 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2024 | 755 | 0.160 |
Why?
|
Argentina | 1 | 2020 | 249 | 0.160 |
Why?
|
Opportunistic Infections | 2 | 2015 | 375 | 0.160 |
Why?
|
Prednisone | 2 | 2019 | 1567 | 0.160 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1273 | 0.160 |
Why?
|
Immunohistochemistry | 4 | 2024 | 11116 | 0.160 |
Why?
|
Disease Progression | 6 | 2024 | 13674 | 0.160 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2024 | 2063 | 0.160 |
Why?
|
Estradiol | 2 | 2017 | 1952 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2021 | 212 | 0.160 |
Why?
|
Ligands | 2 | 2023 | 3283 | 0.160 |
Why?
|
Internationality | 1 | 2024 | 1008 | 0.160 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 472 | 0.160 |
Why?
|
Addison Disease | 1 | 2019 | 48 | 0.160 |
Why?
|
Cancer Vaccines | 2 | 2023 | 1043 | 0.150 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2666 | 0.150 |
Why?
|
Perforin | 1 | 2018 | 167 | 0.150 |
Why?
|
Community-Based Participatory Research | 1 | 2020 | 223 | 0.150 |
Why?
|
Retreatment | 2 | 2020 | 600 | 0.150 |
Why?
|
Nausea | 5 | 2022 | 682 | 0.150 |
Why?
|
Republic of Korea | 1 | 2020 | 592 | 0.150 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 737 | 0.150 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2024 | 2525 | 0.150 |
Why?
|
DNA, Neoplasm | 2 | 2017 | 1748 | 0.150 |
Why?
|
Poisson Distribution | 1 | 2019 | 508 | 0.150 |
Why?
|
Retrospective Studies | 15 | 2025 | 81903 | 0.150 |
Why?
|
Central Nervous System Neoplasms | 2 | 2024 | 930 | 0.140 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2916 | 0.140 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2021 | 682 | 0.140 |
Why?
|
Tamoxifen | 2 | 2013 | 967 | 0.140 |
Why?
|
Morpholines | 1 | 2020 | 584 | 0.140 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6401 | 0.140 |
Why?
|
Hypothyroidism | 2 | 2019 | 667 | 0.140 |
Why?
|
Patient Selection | 4 | 2024 | 4265 | 0.140 |
Why?
|
Incidence | 6 | 2022 | 21547 | 0.140 |
Why?
|
Ovarian Neoplasms | 3 | 2020 | 4919 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2016 | 62 | 0.140 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2024 | 3447 | 0.140 |
Why?
|
Signal Transduction | 5 | 2024 | 23653 | 0.140 |
Why?
|
Hyperglycemia | 2 | 2022 | 1389 | 0.130 |
Why?
|
Thiazoles | 2 | 2022 | 1542 | 0.130 |
Why?
|
North America | 1 | 2020 | 1290 | 0.130 |
Why?
|
Australia | 1 | 2020 | 1265 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2019 | 1793 | 0.130 |
Why?
|
Prospective Studies | 10 | 2024 | 54962 | 0.130 |
Why?
|
Safety | 1 | 2021 | 1161 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1794 | 0.130 |
Why?
|
Europe | 2 | 2020 | 3441 | 0.130 |
Why?
|
Brazil | 1 | 2020 | 1250 | 0.130 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2018 | 594 | 0.130 |
Why?
|
United States | 11 | 2024 | 73186 | 0.130 |
Why?
|
Metformin | 2 | 2020 | 909 | 0.120 |
Why?
|
Guidelines as Topic | 2 | 2021 | 1399 | 0.120 |
Why?
|
Developing Countries | 2 | 2024 | 2911 | 0.120 |
Why?
|
Lung Neoplasms | 6 | 2023 | 13594 | 0.120 |
Why?
|
Pneumocystis carinii | 1 | 2015 | 72 | 0.120 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6320 | 0.120 |
Why?
|
NF-kappa B | 1 | 2023 | 2492 | 0.120 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 271 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2024 | 5892 | 0.120 |
Why?
|
Cell Line, Tumor | 9 | 2024 | 17173 | 0.120 |
Why?
|
Melanoma | 2 | 2023 | 5709 | 0.110 |
Why?
|
Pyrimidines | 2 | 2024 | 3048 | 0.110 |
Why?
|
Phthalazines | 3 | 2024 | 397 | 0.110 |
Why?
|
Proportional Hazards Models | 4 | 2024 | 12562 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.110 |
Why?
|
Male | 26 | 2024 | 365203 | 0.110 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1386 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.110 |
Why?
|
Drug Synergism | 3 | 2024 | 1762 | 0.110 |
Why?
|
Tosyl Compounds | 1 | 2013 | 115 | 0.110 |
Why?
|
Epothilones | 1 | 2013 | 42 | 0.110 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2013 | 108 | 0.110 |
Why?
|
Time Factors | 6 | 2024 | 40261 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 716 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2542 | 0.100 |
Why?
|
Hepatitis C | 1 | 2023 | 1595 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2727 | 0.100 |
Why?
|
Interleukin-6 | 2 | 2024 | 3232 | 0.100 |
Why?
|
Information Dissemination | 1 | 2021 | 1141 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2019 | 2437 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1125 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2021 | 4651 | 0.100 |
Why?
|
Pneumonia | 1 | 2023 | 2164 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2433 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2059 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2023 | 16053 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.090 |
Why?
|
Drug Therapy | 1 | 2014 | 504 | 0.090 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2013 | 423 | 0.090 |
Why?
|
Carcinoma, Papillary | 2 | 2006 | 793 | 0.090 |
Why?
|
Societies, Medical | 2 | 2021 | 3968 | 0.090 |
Why?
|
Estrogen Receptor Modulators | 1 | 2010 | 58 | 0.090 |
Why?
|
Decision Making | 2 | 2021 | 3953 | 0.090 |
Why?
|
Genotype | 3 | 2023 | 13048 | 0.090 |
Why?
|
Factor V | 1 | 2010 | 168 | 0.080 |
Why?
|
Platinum | 2 | 2021 | 222 | 0.080 |
Why?
|
Piperidines | 1 | 2018 | 1667 | 0.080 |
Why?
|
Exercise | 4 | 2021 | 5954 | 0.080 |
Why?
|
Preoperative Care | 2 | 2019 | 2258 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2251 | 0.080 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 489 | 0.080 |
Why?
|
Administration, Oral | 2 | 2014 | 4040 | 0.080 |
Why?
|
Odds Ratio | 2 | 2019 | 9684 | 0.080 |
Why?
|
Biomedical Research | 1 | 2024 | 3463 | 0.080 |
Why?
|
Mice | 9 | 2024 | 82072 | 0.080 |
Why?
|
Genome, Human | 1 | 2021 | 4456 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7603 | 0.080 |
Why?
|
Radiotherapy | 1 | 2015 | 1506 | 0.070 |
Why?
|
Vomiting | 2 | 2022 | 655 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2006 | 631 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3518 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9621 | 0.070 |
Why?
|
Gene Dosage | 2 | 2024 | 1222 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8513 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7453 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2024 | 3621 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3591 | 0.060 |
Why?
|
Survivors | 1 | 2016 | 2383 | 0.060 |
Why?
|
Glioblastoma | 1 | 2021 | 3525 | 0.060 |
Why?
|
Carboplatin | 2 | 2022 | 799 | 0.060 |
Why?
|
Obesity | 2 | 2018 | 13091 | 0.060 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2006 | 225 | 0.060 |
Why?
|
Antiemetics | 1 | 2006 | 188 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20776 | 0.060 |
Why?
|
Risk Factors | 8 | 2023 | 74976 | 0.060 |
Why?
|
Androgen Antagonists | 1 | 2013 | 1421 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 263 | 0.060 |
Why?
|
Oxazepines | 1 | 2024 | 22 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5544 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2021 | 9080 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1811 | 0.060 |
Why?
|
Thromboembolism | 1 | 2010 | 1004 | 0.050 |
Why?
|
Animals | 9 | 2024 | 169335 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 1 | 2013 | 2059 | 0.050 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2024 | 1902 | 0.050 |
Why?
|
Uracil | 1 | 2024 | 210 | 0.050 |
Why?
|
Risk Assessment | 3 | 2024 | 24333 | 0.050 |
Why?
|
Receptors, KIR | 1 | 2023 | 114 | 0.050 |
Why?
|
Thyroid Neoplasms | 2 | 2006 | 2360 | 0.050 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1672 | 0.050 |
Why?
|
Genes, Tumor Suppressor | 1 | 2006 | 1064 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 1 | 2008 | 2598 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2023 | 1151 | 0.050 |
Why?
|
Biology | 1 | 2024 | 292 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2024 | 12467 | 0.050 |
Why?
|
Registries | 3 | 2023 | 8384 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2819 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2024 | 673 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 246 | 0.050 |
Why?
|
Inflammation | 1 | 2020 | 10868 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6982 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2024 | 475 | 0.040 |
Why?
|
Gene Silencing | 1 | 2006 | 1505 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6512 | 0.040 |
Why?
|
Immunotoxins | 1 | 2020 | 175 | 0.040 |
Why?
|
Organ Specificity | 1 | 2024 | 1970 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2023 | 564 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 330 | 0.040 |
Why?
|
Receptors, Steroid | 1 | 2020 | 156 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 644 | 0.040 |
Why?
|
Hypoglycemic Agents | 2 | 2024 | 3110 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2024 | 645 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2006 | 984 | 0.040 |
Why?
|
Alleles | 2 | 2022 | 6901 | 0.040 |
Why?
|
Cell Death | 1 | 2024 | 1682 | 0.040 |
Why?
|
Dexamethasone | 1 | 2006 | 1965 | 0.040 |
Why?
|
Transplantation Conditioning | 1 | 2006 | 1601 | 0.040 |
Why?
|
Fever | 1 | 2006 | 1619 | 0.040 |
Why?
|
Workflow | 1 | 2023 | 859 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18068 | 0.040 |
Why?
|
Thrombocytopenia | 2 | 2018 | 1181 | 0.040 |
Why?
|
Observer Variation | 1 | 2024 | 2623 | 0.040 |
Why?
|
Mind-Body Therapies | 1 | 2021 | 294 | 0.040 |
Why?
|
Imidazoles | 1 | 2024 | 1169 | 0.040 |
Why?
|
Patient Care | 1 | 2023 | 629 | 0.040 |
Why?
|
Weight Loss | 2 | 2021 | 2721 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 961 | 0.040 |
Why?
|
Computational Biology | 2 | 2021 | 3562 | 0.040 |
Why?
|
Prevalence | 3 | 2024 | 15879 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 980 | 0.040 |
Why?
|
Body Composition | 2 | 2017 | 2462 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2022 | 4207 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.040 |
Why?
|
Premenopause | 1 | 2021 | 1039 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 651 | 0.030 |
Why?
|
Anemia | 2 | 2019 | 1517 | 0.030 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 2041 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10276 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2013 | 6673 | 0.030 |
Why?
|
Central Nervous System | 1 | 2022 | 1346 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2023 | 3744 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1887 | 0.030 |
Why?
|
Patient Preference | 1 | 2022 | 947 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1742 | 0.030 |
Why?
|
Hematologic Neoplasms | 1 | 2006 | 1907 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36854 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2016 | 428 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3810 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2893 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3214 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2574 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 193 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 149 | 0.030 |
Why?
|
DNA Methylation | 1 | 2006 | 4432 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 13021 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1769 | 0.020 |
Why?
|
Peptides | 1 | 2024 | 4353 | 0.020 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18354 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1780 | 0.020 |
Why?
|
Stomatitis | 1 | 2013 | 271 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2022 | 8144 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2022 | 4785 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2022 | 5323 | 0.020 |
Why?
|
Algorithms | 2 | 2022 | 14201 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3813 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1741 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2016 | 965 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
Autoimmunity | 1 | 2018 | 1360 | 0.020 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2010 | 131 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3438 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2016 | 1111 | 0.020 |
Why?
|
Macrophages | 1 | 2024 | 5801 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3631 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1645 | 0.020 |
Why?
|
Blood Glucose | 1 | 2024 | 6435 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4124 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1099 | 0.020 |
Why?
|
Reference Values | 1 | 2016 | 4940 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3859 | 0.020 |
Why?
|
Remission Induction | 1 | 2014 | 2408 | 0.020 |
Why?
|
Mitosis | 1 | 2013 | 1181 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2013 | 1340 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3608 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3629 | 0.020 |
Why?
|
Apoptosis | 1 | 2023 | 9527 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5100 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14794 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 34 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11684 | 0.020 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2006 | 81 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2016 | 2009 | 0.020 |
Why?
|
Sirolimus | 1 | 2013 | 1540 | 0.020 |
Why?
|
DNA Repair | 1 | 2016 | 2054 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2017 | 2784 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 1892 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2597 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2006 | 229 | 0.020 |
Why?
|
Rats | 1 | 2022 | 23786 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2016 | 22296 | 0.020 |
Why?
|
Life Style | 1 | 2017 | 3931 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2812 | 0.020 |
Why?
|
Postmenopause | 1 | 2014 | 2519 | 0.020 |
Why?
|
Histones | 1 | 2016 | 2603 | 0.020 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 492 | 0.020 |
Why?
|
Myeloablative Agonists | 1 | 2006 | 210 | 0.020 |
Why?
|
Self Report | 1 | 2016 | 3773 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8317 | 0.010 |
Why?
|
Mucositis | 1 | 2006 | 108 | 0.010 |
Why?
|
Etoposide | 1 | 2006 | 639 | 0.010 |
Why?
|
Cation Transport Proteins | 1 | 2006 | 326 | 0.010 |
Why?
|
DNA Damage | 1 | 2013 | 2472 | 0.010 |
Why?
|
Software | 1 | 2017 | 4479 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2016 | 9565 | 0.010 |
Why?
|
Mammaplasty | 1 | 2013 | 1263 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10486 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 22379 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8749 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 622 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2014 | 2057 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5216 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5804 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2006 | 2126 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10592 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7460 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4592 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2010 | 12095 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13318 | 0.010 |
Why?
|
Graft Survival | 1 | 2006 | 3888 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11230 | 0.010 |
Why?
|
Adolescent | 1 | 2022 | 89244 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 8617 | 0.010 |
Why?
|
Smoking | 1 | 2010 | 9094 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15889 | 0.010 |
Why?
|
Heart Failure | 1 | 2014 | 11879 | 0.010 |
Why?
|